GlobeImmune, Inc : GlobeImmune Initiates Phase 2 Study of a Novel T Cell Stimulating Cancer Vaccine (GI-6207) Targeting CEA in

   GlobeImmune, Inc : GlobeImmune Initiates Phase 2 Study of a Novel T Cell
Stimulating Cancer Vaccine (GI-6207) Targeting CEA in Patients with Metastatic
                           Medullary Thyroid Cancer

LOUISVILLE, Colo.,  April 3,  2013 -  GlobeImmune, Inc.,  announced today  the 
initiation of a Phase 2 clinical trial at the National Cancer Institute  (NCI) 
to evaluate GI-6207 in subjects with medullary thyroid cancer (MTC). Ravi  A. 
Madan, M.D., at the NCI Medical Oncology / Laboratory of Tumor Immunology  and 
Biology is  the  Principal  Investigator  for this  study.  GI-6207  is  being 
developed as  part  of  a Collaborative  Research  and  Development  Agreement 
between the NCI and GlobeImmune.

GI-6207-02 is a randomized Phase 2 study that is planned to enroll a total  of 
34 patients  in a  cross-over trial  design. Patients  will be  treated  with 
either GI-6207 for one  year or be  observed for six  months and then  treated 
with GI-6207 for one  year. The primary  endpoint for the  trial will be  the 
effect of GI-6207 on changes in calcitonin levels after six months of  GI-6207 
treatment vs. observation. Calcitonin is a tumor marker that correlates  with 
tumor  size  in  MTC.  Elevated  calcitonin  values  after  surgery  indicate 
persistent or recurrent disease.

"We believe  that  MTC is  an  excellent clinical  indication  for  Tarmogen^® 
immunotherapy," said  David Apelian,  M.D., Ph.D.,  Chief Medical  Officer  at 
GlobeImmune. "Observation  is  the  current standard  of  care  for  minimally 
symptomatic MTC with low tumor burden. However, in this setting we believe we
will be  able to  evaluate GI-6207-induced  immune responses  and  potentially 
correlate them with calcitonin levels in a short time frame."

Medullary Thyroid Cancer

Thyroid cancer is  the most common  type of endocrine  malignancy in the  U.S. 
with approximately  56,000 new  cases  in 2012.  MTC,  a subtype  of  thyroid 
cancer, is  aggressive,  spreads  quickly  and  has  a  poor  prognosis,  with 
approximately 25 percent  and 10  percent of patients  alive at  five and  ten 
years, respectively. Surgery  is currently  the only  curative treatment  for 
MTC. Two drugs have been approved for the treatment of metastatic MTC.  Both 
of these products  were approved  on the  basis of  improved progression  free 
survival; neither  has yet  shown improved  overall survival.  Both of  these 
products have  significant side  effect  profiles that  include  hypertension, 
nausea, diarrhea, cardiac arrhythmias and thrombotic or bleeding episodes.


The GI-6207 Tarmogen consists of whole, heat-killed, recombinant S. cerevisiae
yeast genetically  engineered  to express  a  modified version  of  the  human 
carcinoembryonic antigen (CEA) protein as  the target cancer antigen. CEA  is 
over-expressed in multiple human epithelial cancers, including MTC, where  CEA 
is almost universally expressed  and is a diagnostic  marker of the  disease. 
Preclinical studies have shown that GI-6207  can induce an immune response  to 
CEA as well as therapeutic anti-tumor responses. A previous Phase 1 study  of 
monotherapy GI-6207 demonstrated preliminary safety and tolerability, enhanced
immune responses  and  stable disease  in  20%  of subjects  (5/25)  beyond  3 

About GlobeImmune

GlobeImmune is a biopharmaceutical company focused on developing products  for 
the treatment  of cancer  and  infectious diseases  based on  its  proprietary 
Tarmogen  platform.  Tarmogens  activate  the  immune  system  by  stimulating 
cellular immunity,  known  as T  cell  immunity, in  contrast  to  traditional 
vaccines that predominately stimulate antibody production. To date,  Tarmogen 
product candidates have been generally  well tolerated in clinical trials  for 
multiple disease indications and are  efficient to manufacture. In May  2009, 
the company entered  into a collaboration  agreement with Celgene  Corporation 
focused  on  the  discovery,  development  and  commercialization  of  product 
candidates for the treatment of cancer. In October 2011, the company  entered 
into a  worldwide,  strategic collaboration  with  Gilead Sciences,  Inc.,  to 
develop Tarmogens  for the  treatment of  chronic hepatitis  B infection.  For 
additional   information,   please    visit   the    company's   website    at


Safe Harbor Statement

This press release contains "forward-looking  statements" for purposes of  the 
safe harbor provided by the Private Securities Litigation Reform Act of  1995. 
These statements include,  but are  not limited to,  statements regarding  the 
potential for GI-6207 to target  medullary thyroid cancers expressing CEA  and 
Tarmogen's  potential  side   effect  profiles,  the   Company's  ability   to 
successfully complete  clinical  trials,  timing and  eventual  prospects  for 
approval to market  any of the  Company's products and  the prospects for  the 
Company's collaborations. Such  statements are based  on management's  current 
expectations  and  involve  risks   and  uncertainties.  Actual  results   and 
performance  could   differ   materially   from   those   projected   in   the 
forward-looking statements as  a result  of many  factors, including,  without 
limitation,  the  risks  and  uncertainties  associated  with:  the  Company's 
financial resources and whether they will be sufficient to meet the  Company's 
business objectives and operational  requirements; results of earlier  studies 
and trials  may  not be  predictive  of  future clinical  trial  results,  the 
protection and  market  exclusivity  provided by  the  Company's  intellectual 
property; risks  related to  the drug  discovery and  the regulatory  approval 
process; and, the  impact of competitive  products and technological  changes. 
The Company disclaims any intent or obligation to update these forward-looking

GlobeImmune Contact:
David Apelian, M.D., Ph.D., M.B.A.
Chief Medical Officer
T: 303-625-2820

GlobeImmune Media Contacts:
Lena Evans or Tony Russo, Ph.D.
Russo Partners, LLC
T: 212-845-4262 or 212-845-4251


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: GlobeImmune, Inc via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.